NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

疫苗市場:全球產業分析(2017年∼2020年)- 成長趨勢與市場預測(2021年∼2025年)

Vaccines Market - Global Industry Analysis (2017 - 2020) - Growth Trends and Market Forecast (2021 - 2025)

出版商 Fairfield Market Research 商品編碼 1006904
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
疫苗市場:全球產業分析(2017年∼2020年)- 成長趨勢與市場預測(2021年∼2025年) Vaccines Market - Global Industry Analysis (2017 - 2020) - Growth Trends and Market Forecast (2021 - 2025)
出版日期: 2021年02月01日內容資訊: 英文 170 Pages
簡介

全球疫苗市場,預計從2020年到2025年的預測期間內以10.2%的年複合成長率成長,從2020年的335億7,250萬美元到2025年達到546億8,480萬美元。該市場,由於抑制COVID-19大流行的疫苗接種的需求持續緊急發生,預計從2020年到2025年收益劇增。各國政府支援各種製藥公司疫苗的研究、製造,對該市場也帶來好的影響。

COVID-19代表的感染疾病增加產生需求,帶給市場著急速成長和機會。預計全球疫苗市場在給藥回數中,以6.5%的年複合成長率成長,從2020年的55億9,540萬次,預計2025年達到76億7,510萬次。

本報告提供全球疫苗市場的相關調查,市場成長及阻礙因素,機會,各疫苗、國家群組、企業、地區的市場分析,競爭情形,市場佔有率,主要企業的簡介等資訊。

目錄

第1章 摘要整理

  • 全球疫苗市場預測,銷售額及給藥回數(2017-2025)
  • 全球疫苗的增量機會,銷售額及給藥回數(2020-2025)
  • 要點

第2章 市場概要

  • 市場區隔和定義
  • 市場動態
    • 市場成長要素
    • 市場阻礙因素
    • 市場機會
  • COVID-19的影響分析

第3章 疫苗的供給動態

  • 疫苗的供給

第4章 疫苗的價格分析

  • 疫苗的價格
  • 疫苗價格的變更

第5章 全球疫苗市場預測:各疫苗(2017-2025)

  • 主要的焦點
  • 全球市場預測:各疫苗銷售額及給藥回數(2017-2025)
    • PCV
    • 二種混合(DT)
    • HPV
    • 季節性流感
    • 帶狀皰疹
    • 輪狀病毒
    • 腦膜炎
    • MCV
    • 水痘
    • COVID-19(新型冠狀病毒感染疾病)
    • 其他
  • 全球市場佔有率和BPS分析(2020,2025)
  • 市場魅力分析(2020-2025)

第6章 全球疫苗市場預測:各國家群組(2017-2025)

  • 主要的焦點
  • 全球市場預測:各國家群組銷售額及給藥回數(2017-2025)
    • PAHO RF(全美保健機構)
    • 自採購HIC(高所得國)
    • 自採購MIC(中所得國)
    • UNICEF(GAVI-疫苗和疫苗接種的全球聯盟)
    • UNICEF採購MIC(中所得國)
  • 全球市場佔有率和BPS分析(2020,2025)
  • 市場魅力分析(2020-2025)

第7章 全球疫苗市場預測:各地區(2017-2025)

  • 主要的焦點
  • 全球市場預測:各區域銷售額及給藥回數(2017-2025)
    • 非洲(AFRO)
    • 南北美洲(AMRO)
    • 東地中海(EMRO)
    • 歐洲(EURO)
    • 東南亞(SEARO)
    • 西太平洋(WPRO)
  • 全球市場佔有率和BPS分析(2020,2025)
  • 市場魅力分析(2020-2025)

第8章 全球疫苗市場預測:各企業(2017-2025)

  • 主要的焦點
  • 全球市場預測:各企業銷售額及給藥回數(2017-2025)
    • AstraZeneca
    • GlaxoSmithKline plc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Novavax
    • Pfizer Inc.
    • Sanofi Pasteur
    • 其他
  • 全球市場佔有率和BPS分析(2020,2025)
  • 市場魅力分析(2020-2025)

第9章 競爭情形

  • 企業的市場佔有率分析(2019)
  • 企業簡介
    • CSL Limited (Seqirus)
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline plc.
    • Haffkine Bio-pharmaceutical Corporation Ltd.
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Moderna
    • Novavax
    • Pfizer Inc.
    • Sanofi Pasteur
    • Serum Institute of India Pvt. Ltd.
    • Sinopharm

第10章 附錄

  • 調查手法
  • 簡稱
目錄

The global vaccines market is poised to witness a spike in earnings between 2020 and 2025 as the demand for immunization to curb the COVID-19 pandemic remains urgent. Unflinching support from the governments for the research and manufacturing of vaccines across various pharmaceutical facilities is expected to bode well for the market. A recent report published by Fairfield Market Research indicates the market will register a 10.2% CAGR during the forecast period of 2020 to 2025. The global market is expected to reach US$54,684.8 Mn by 2025 from US$33,572.5 Mn in 2020.

The rise of infectious diseases, such as COVID-19, has generated an immediate demand, creating a short-term spike and opportunity for the market. In terms of volume, the global Vaccines market is expected to attain a 6.5%CAGR. The global vaccines market is expected to reach 5,595.4 Mn doses in 2020 to 7,675.1 Mn doses in 2025.

Key Highlights for Global Vaccines Market:

Shingles vaccine eyes has the highest CAGR among vaccines with 15.5% in terms of value and 11.6% in terms of volume during the forecast period

Americas (AMRO) to stand out as a region in terms of revenue while South and East Asia (SEARO) is the leading region with the highest volume by end of the forecast period

Within the country group, self-procuring, high-income countries (HICs) to acquire a market share of 65% by 2025 in terms of revenue. Meanwhile, self-procuring middle-income countries (MICs) to reach 51% by 2025 in terms of volume

Vaccine manufacturing remains concentrated with four large manufacturers - GlaxoSmithKline plc., Pfizer Inc., Merck KGaA, and Sanofi - who control 90% of global Vaccines market value

Mid-size manufacturers, mostly in Asia, are expanding their portfolios to compete in regional and new Vaccines markets, such as HPV and PCV, offering additional and often more affordable choices.

Pneumococcal Conjugate Vaccine's Popularity in Developing Countries to Keep Segment in the Lead

According to the World Health Organization, vaccination for pneumococcal diseases is carried out across 42 countries, including the most populated ones such as India and China. These diseases continue to be the key cause of mortality amongst children and adults. The most commonly seen form of pneumococcal diseases are pneumonia and meningitis. Efforts to reduce the pressure on healthcare systems and improve life spans is expected to retain pneumococcal conjugate vaccine's (PCV) status as indispensable across immunization program. These factors are estimated to keep the segment in the lead during the forecast period.

COVID-19 becomes Turning Point for Asia Pacific to Attain Leadership in Global Vaccines Market

Fairfield Market Research indicates that the Asia Pacific vaccines market is paving the way as developing economies have immunization programs that developed countries do not have. Vaccination strategies in developing countries are primarily meant for public health intervention to contain the spread of diseases such as polio, measles, meningitis, and others. Furthermore, as most of the countries in Asia Pacific are under The Global Alliance for Vaccines and Immunizations (GAVI), the regional market is expected to lead in the forthcoming years.

In addition, India's leadership in COVID-19 vaccine production and distribution is also expected to contribute to the regional market. With two top contenders based in India, Serum Institute of India Pvt. Ltd. and Bharat Biotech are expected to be the biggest providers of national immunization for their own citizens and cater to the world's vaccine need. Thus, Fairfield Market Research anticipates that the pandemic will tip the balance in favour of Asia Pacific vaccines market throughout the forecast period.

Difficult to Crack Barrier to Entry Prevents Competition in Vaccines Market

The global vaccines market is tightly held by few players, making it oligopolistic. GlaxoSmithKline plc., Pfizer Inc., Merck KGaA, and Sanofi hold a lion's share of 90% in the global market in terms of value, while Serum Institute of India Pvt. Ltd., Bharat Biotech, Sanofi, and GlaxoSmithKline plc. manufacture 60% of the vaccines. As research, development, and production remains a highly knowledge-based process, the market has inherent high standards that are difficult to crack for the new entrants. Furthermore, the capital-intensive nature of setting up production units that demand utmost precision, continuous monitoring, top clearances, and unbreachable storage facilities make it difficult for new players to crack the code.

The key players studied in this report are China National Pharmaceutical Group Corporation (Sinopharm), Serum Institute of India Pvt. Ltd., Novavax, Moderna, Mitsubishi Tanabe Pharma Corporation, Emergent BioSolutions Inc., and CSL Limited (Seqirus).

Table of Contents

1. Executive Summary

  • 1.1. Global Vaccines Market Outlook, Value (US$ Million) and Volume (Number of Doses) (Million), 2017 - 2025
  • 1.2. Global Vaccines Incremental Opportunity, Value (US$ Million) and Volume (Million), 2020 - 2025
  • 1.3. Key Takeaways

2. Market Overview

  • 2.1. Market Segmentations and Definitions
  • 2.2. Market Dynamics
    • 2.2.1. Market Drivers
    • 2.2.2. Market Restraints
    • 2.2.3. Market Opportunities
  • 2.3. COVID-19 Impact Analysis

3. Vaccines Supply Dynamics

  • 3.1. Vaccines Supply

4. Vaccines Pricing Analysis

  • 4.1. Vaccine Prices
  • 4.2. Vaccine Price Changes

5. Global Vaccines Market Outlook, By Vaccine, 2017-2025

  • 5.1. Key Highlights
  • 5.2. Global Vaccines Market Outlook, by Vaccine, Value (US$ Million) and Volume (million), 2017 - 2025
    • 5.2.1. PCV
    • 5.2.2. D&T-containing
    • 5.2.3. HPV
    • 5.2.4. Seasonal Influenza
    • 5.2.5. Shingles
    • 5.2.6. Rotavirus
    • 5.2.7. Meningococcal
    • 5.2.8. MCVs
    • 5.2.9. Varicella
    • 5.2.10. COVID-19
    • 5.2.11. Others
  • 5.3. Global Vaccines Market Share and BPS(Basis Points) Analysis, by Vaccine, 2020 and 2025
  • 5.4. Global Vaccines Market Attractiveness Analysis, by Vaccine, 2020-2025

6. Global Vaccines Market Outlook, By Country Group , 2017-2025

  • 6.1. Key Highlights
  • 6.2. Global Vaccines Market Outlook, by Country Group, Value (US$ Million) and Volume (million), 2017 - 2025
    • 6.2.1. PAHO RF (Pan American Health Organization)
    • 6.2.2. Self-procuring HICs(High Income Countries)
    • 6.2.3. Self-procuring MICs(Middle Income Countries)
    • 6.2.4. UNICEF (GAVI - Global Alliance for Vaccines and Immunizations )
    • 6.2.5. UNICEF-procuring MICs(Middle Income Countries)
  • 6.3. Global Vaccines Market Share and BPS(Basis Points) Analysis, by Country Group, 2020 and 2025
  • 6.4. Global Vaccines Market Attractiveness Analysis, by Country Group, 2020-2025

7. Global Vaccines Market Outlook, By Region, 2017-2025

  • 7.1. Key Highlights
  • 7.2. Global Vaccines Market Outlook, by Region, Value (US$ Million) and Volume (million), 2017 - 2025
    • 7.2.1. Africa (AFRO)
      • 7.2.1.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.1.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.1.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.1.4. Vaccines Supply and Pricing Analysis
      • 7.2.1.5. List of Manufacturers in the Region, By Vaccine
    • 7.2.2. Americas (AMRO)
      • 7.2.2.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.2.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.2.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.2.4. Vaccines Supply and Pricing Analysis
      • 7.2.2.5. List of Manufacturers in the Region, By Vaccine
    • 7.2.3. Eastern Mediterranean (EMRO)
      • 7.2.3.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.3.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.3.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.3.4. Vaccines Supply and Pricing Analysis
      • 7.2.3.5. List of Manufacturers in the Region, By Vaccine
    • 7.2.4. Europe (EURO)
      • 7.2.4.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.4.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.4.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.4.4. Vaccines Supply and Pricing Analysis
      • 7.2.4.5. List of Manufacturers in the Region, By Vaccine
    • 7.2.5. South and East Asia (SEARO)
      • 7.2.5.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.5.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.5.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.5.4. Vaccines Supply and Pricing Analysis
      • 7.2.5.5. List of Manufacturers in the Region, By Vaccine
    • 7.2.6. Western Pacific (WPRO)
      • 7.2.6.1. Market Share Analysis, By Value (US$ Million), 2019
      • 7.2.6.2. Market Share Analysis, By Dosage (US$ Million), 2019
      • 7.2.6.3. Market Share Analysis, By Procurement Method (US$ Million), 2019
      • 7.2.6.4. Vaccines Supply and Pricing Analysis
      • 7.2.6.5. List of Manufacturers in the Region, By Vaccine
  • 7.3. Global Vaccines Market Share and BPS(Basis Points) Analysis, by Region, 2020 and 2025
  • 7.4. Global Vaccines Market Attractiveness Analysis, by Region, 2020-2025

8. Global Vaccines Market Outlook, By Company, 2017-2025

  • 8.1. Key Highlights
  • 8.2. Global Vaccines Market Outlook, by Company, Value (US$ Million) and Volume (million), 2017 - 2025
    • 8.2.1. AstraZeneca
    • 8.2.2. GlaxoSmithKline plc.
    • 8.2.3. Johnson & Johnson
    • 8.2.4. Merck & Co., Inc.
    • 8.2.5. Moderna, Inc.
    • 8.2.6. Novavax
    • 8.2.7. Pfizer Inc.
    • 8.2.8. Sanofi Pasteur
    • 8.2.9. Others
  • 8.2. Global Vaccines Market Share and BPS(Basis Points) Analysis, by Company, 2020 and 2025
  • 8.3. Global Vaccines Market Attractiveness Analysis, by Company, 2020-2025

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2019
  • 9.2. Company Profiles
    • 9.3.1. CSL Limited (Seqirus)
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product Portfolio
      • 9.2.1.4. Research and Development
      • 9.2.1.5. Recent Developments
    • 9.3.2. Emergent BioSolutions Inc.
    • 9.3.3. GlaxoSmithKline plc.
    • 9.3.4. Haffkine Bio-pharmaceutical Corporation Ltd.
    • 9.3.5. Merck & Co., Inc.
    • 9.3.6. Mitsubishi Tanabe Pharma Corporation
    • 9.3.7. Moderna
    • 9.3.8. Novavax
    • 9.3.9. Pfizer Inc.
    • 9.3.10. Sanofi Pasteur
    • 9.3.11. Serum Institute of India Pvt. Ltd.
    • 9.3.12. Sinopharm

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Acronyms and Abbreviations